Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling

Current clinical RAF inhibitors (RAFi) inhibit monomeric BRAF (mBRAF), but are less potent against dimeric BRAF (dBRAF). RAFi equipotent for mBRAF and dBRAF have been developed, but are predicted to have lower therapeutic index. Here we identify a third class of RAFi that selectively inhibits dBRAF...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Adamopoulos, Christos, Ahmed, Tamer A., Tucker, Maxwell R., Ung, Peter M.U., Xiao, Min, Karoulia, Zoi, Amabile, Angelo, Wu, Xuewei, Aaronson, Stuart A., Ang, Celina, Rebecca, Vito W., Brown, Brian D., Schlessinger, Avner, Herlyn, Meenhard, Wang, Qi, Shaw, David E., Poulikakos, Poulikos I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8295204/
https://ncbi.nlm.nih.gov/pubmed/33568355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-1351
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados